In an effort to understand the potential change in investment incentives under the drug price negotiation provisions of the Inflation Reduction Act of 2022, Henry Grabowski and coauthors examine clinical trials and approvals for new indications after the initial approval of cancer drugs.
They find that more than half of all indications are postapproval, with about half of these indications reflecting new disease areas for the drug and most drugs having at least one orphan drug indication.
Olivier Wouters and Jouni Kuha examine the timing of drug launches around the world for the World Health Organization’s designated essential medicines.
The median time from first launch to availability was less than three years for high-income countries but almost seven years for lower-middle-income countries and eight years for low-income countries, demonstrating significant inequities.
Medicare Part D plans are required to cover “all or substantially all” drugs in six protected classes.
Pragya Kakani and coauthors find that this translates into low rates of formulary exclusions and a rate of growth in average rebates during 2011–19 about one-sixth for protected-class drugs relative to those not in a protected class.
Although Paxlovid is an effective drug for high-risk patients with COVID-19, Gillian SteelFisher and coauthors analyze survey data and find that about 85 percent of Americans report no or low awareness of it.
Low awareness is most common among those who could benefit most from the drug, and misperceptions regarding its effectiveness and how to use it are widespread.